Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3836402 | 0.77 | CYP3A4 (0.39) | CYP3A4CYP2C19HIF1ASLC6A9OPRM1 | |
| SCHEMBL15059997 | 0.77 | FFAR1 (0.44) | CYP3A4CYP2C19HIF1AFFAR1AKR1C1 | |
| SCHEMBL2008405 | 0.77 | AVPR1A (0.40) | USP2ALDH1A1HSD17B10CYP1A2TSHR | |
| SCHEMBL27627652 | 0.76 | CYP2C19 (0.38) | CYP3A4CYP2C19HIF1ASLC6A9OPRM1 | |
| SCHEMBL474607 | 0.76 | CYP3A4 (0.44) | CYP3A4CYP2C19HIF1AFFAR1AKR1C1 | |
| SCHEMBL2733709 | 0.76 | NR1H2 (0.52) | CYP3A4CYP2C19HIF1ASLC6A9OPRM1 | |
| SCHEMBL30668922 | 0.76 | NR1H2 (0.52) | CYP3A4CYP2C19HIF1ASLC6A9OPRM1 | |
| SCHEMBL2733711 | 0.76 | NR1H2 (0.52) | CYP3A4CYP2C19HIF1ASLC6A9OPRM1 | |
| Hydrochloric Acid SCHEMBL29256930 | 0.75 | NR1H2 (0.51) | CYP3A4CYP2C19HIF1ASLC6A9OPRM1 | |
| Hydrochloric Acid SCHEMBL29256931 | 0.75 | NR1H2 (0.51) | CYP3A4CYP2C19HIF1ASLC6A9OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718802-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7326707-B2 | Bicyclic melanocortin-specific compounds | PALATIN TECHNOLOGIES INCORPORATED (US) | 2008-02-05 | — | — | US | disclosed |
| WO-2005102340-A1 | PIPERAZINE MELANOCORTIN-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | MC3R, MC4R, MC1R | CYP3A4 2689/4885CYP2C19 1626/4885HIF1A 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.